Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Hyperion Therapeutics Announces Results Of Phase I Study In Patients With Liver Cirrhosis
Hyperion Therapeutics, Inc. announced top-line results from a phase I study of HPN-100 in patients with liver cirrhosis. The data were presented as part of the 2009 Digestive Disease Week meeting. The abstract is titled "Pharmacokinetic (PK) and Safety Analyses of a Novel Ammonia-Reducing Agent in Healthy Adults and Patients with Cirrhosis."

Senate Finance Committee Releases Policy Paper Describing Options To Pay For Health Overhaul
Senate Finance Committee Chair Max Baucus (D-Mont.) and ranking member Chuck Grassley (R-Iowa) on Monday released a 41-page document outlining policy options for financing health care reform, The Hill reports (Young, The Hill, 5/18). The paper is the third and final to be released before the senators draft health reform legislation. The document says Baucus and Grassley do not support all the proposals included in the paper, but does not indicate which are backed by the senators (Wayne, CQ Today, 5/18). The options, which will be discussed at a closed-door committee meeting on Wednesday, include a number of proposed spending cuts and new or revised taxes (Drucker, Roll Call, 5/18). The report outlines several ways to gain revenue by re-evaluating the tax exemption for employer-sponsored health care benefits, which cost the government $194.2 billion in revenue in 2008, according to the report. The options include:
News of the day
Health And Safety Executive Warns Of Dangers In Failing To Maintain Plant Equipment After Driver's Death, UK
The Health and Safety Executive has warned of the danger of not maintaining plant equipment after the death of a telescopic forklift truck driver, who was crushed between the descending arm and side of his vehicle.
Public Health

Olympus Broadens Portfolio With New Biliary Metallic Stent

Olympus America Inc. has expanded its medical portfolio by introducing the X-Suit NIR®, a biliary metallic stent designed with exceptional anatomic conformability and superior radial support. The X-Suit NIR"s proprietary NIRflex™ cell design provides a physician support and flexibility; both critical to help relieve the symptoms associated with pancreatic, liver and bile duct cancers. The NIRflex™ advanced cell design biliary metallic stent provides flexible construction to fit the shape of any biliary duct. Constructed of Nitinol, the stent is water-jet cut and electro-polished for much greater durability. Each strut is also rounded, helping to reduce stress to the tissue and prevent damage to the bile duct and duodenal walls. "Olympus provides the most extensive line of GI products and services in the industry," said Eric Halvorson, chief marketing officer, Medical Systems Group, Olympus America, Inc. "X-Suit is a good example of how Olympus remains dedicated to expanding its offerings and working with the world"s top medical experts to provide solutions that best suit the needs of its customers and their patients." To ensure precise placement of the stent during a therapeutic procedure, the X-Suit NIR® has virtually no foreshortening. In addition, each end of the stent features five radiopaque markers that allow physicians to determine the position of the stent under an X-ray prior to deployment. A black marker is positioned at the proximal end of the stent facilitating endoscopic confirmation of the stent during deployment. The ease of deployment combined with superior radial support makes the X-Suit NIR® the stent of choice for re-establishing biliary flow. Lisa Koen Golin/Harris International


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009